期刊文献+

酒精性肝炎患者不同治疗方案的疗效观察 被引量:2

Analysis of different protocols in treatment of alcoholic hepatitis
下载PDF
导出
摘要 目的:探讨不同治疗方案对酒精性肝炎患者的治疗效果。方法选择酒精性肝炎患者128例,随机分为研究组(48例)、对照1组(40例)及对照2组(40例),研究组给予异甘草酸镁注射液150 mg,1次/d静脉滴注;对照1组予以还原型谷胱甘肽1.2 g,1次/d静脉滴注;对照2组予以硫普罗宁0.2 g,1次/d静脉滴注,治疗时间2周~3周。结果研究组腹胀、纳差、乏力、黄疸、肝脏肿大和压痛减轻率均高于对照1组、对照2组(均P〈0.05)。研究组治疗后丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、谷氨酰转肽酶(GGT)、总胆红素的水平均低于对照1组、对照2组(P〈0.01)。结论异甘草酸镁对于控制酒精性肝炎炎症活动有显著作用,且优于还原型谷胱甘肽、硫普罗宁。 Objective To analyse and compare the effectiveness of different protocols on alcoholic hepatitis. Methods 128 patients were randomly divided into treatment group(n=48)、control group 1(n=40) and control group 2 (n=40).Patients in the treatment group were given magnesium isoglycyrrhizinate 150 mg once every day. Patients in the control group 1 were given reduced glutathione 1.2 g once every day. Patients in the control group 2 were given tiopronin 0.2g once everyday.The Course was 2~3 weeks. Results Patients in three groups showed therapeutic effect with statistical significance(P〈0.05).After treatment.the degree of biochemieal indicators declined significantly inthe treatment group than that of the control groups(P〈0.01).Conclusion The result shows that magnesium isoglycyrrhizinate、reduced glutathione and tiopronin are effective drugs for controlling inffanunation activity of thealcoholic hepatitis and magnesium isoglycyrrhizinate is a more effective and safer agent than reduced glutathione and tiopronin.
作者 彭明 余玲
出处 《基层医学论坛》 2014年第4期412-414,共3页 The Medical Forum
关键词 酒精性肝炎 异甘草酸镁 还原型谷胱甘肽 硫普罗宁 Alcoholic hepatitis Magnesium isoglycyrrhizinate Reduced glutathione Tiopronin
  • 相关文献

参考文献4

二级参考文献18

  • 1王佩,吴锡铭.异甘草酸镁对大鼠四氯化碳慢性肝损伤的治疗作用[J].中国新药与临床杂志,2004,23(12):833-836. 被引量:109
  • 2胡国平,刘凯,赵连三.多烯磷脂酰胆碱(易善复)治疗酒精性肝病和脂肪肝的系统评价[J].肝脏,2005,10(1):5-7. 被引量:108
  • 3董丽萍,于锋,柳静,穆先敏.异甘草酸镁对D-氨基半乳糖急性肝损伤模型小鼠的保护作用研究[J].中国药房,2006,17(12):902-904. 被引量:93
  • 4Lok AS,McMahon B J; Practice Guidelines Committee,American Association for the Study of Liver Diseases (AASLD).Chronic hepatitis B:update of recommendations.Hepatology,2004,39:857-861.
  • 5Sanyal AJ.American Gastroenterological Association technical review on nonalcoholic fatty liver disease.Gastroenterology,2002,123:1705-1725.
  • 6Graif M,Yanuka M,Baraz M,et al.Quantitative estimation of attenuation in ultrasound video images:correlation with histology in diffuse liver disease.Invest Radiol,2000,35:319-324.
  • 7Ataseven H,Yildrim MH,Yalniz M,et al.Correlation between computerized tomographic findings and histopathologic grade/stage in non-alcoholic steatohepatitis.J Hepatol,2003,38(Suppl 2):A4177.
  • 8Farrell GC,George J,Pauline de la M.Hall,et al,eds.Fatty liver diseas:NASH and related disorders.Oxford:Blackwell Publishing,2005.159-207.
  • 9McCullough AJ,O'Connor JF.Alcoholic liver disease:proposed recommendations for the American College of Gastroenterology.Am J Gastroenterol,1998,93:2022-2036.
  • 10Stickel F,Hoehn B,Schuppan D,et al.Review article:Nutritional therapy in alcoholic liver disease.Aliment Pharmacol Ther,2003,18:357-373.

共引文献342

同被引文献19

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部